Investigating the Micrornas as Key Regulator in Diabetic Cardiomyopathy

Abstract

Diabetic Cardiomyopathy (DCM) is a state in which cardiomyopathy occurs in patients due to diabetes mellitus without valvular and coronary artery disease. The DCM prevalence is about 50% in patients diagnosed with diabetes at either clinical or preclinical stages. DCM is characterized by structural and metabolic myocardial changes established in patients with diabetes mellitus. These changes are triggered by insulin resistance and hyperinsulinemia that lead to the dysregulation of different signaling pathways. Despite the improvement in pharmacological interventions in DCM, still, new reliable strategies are required. MicroRNAs are small non-coding molecules that play a significant role in the regulation of genes at transcriptional and translational levels. We have found the clinical tested genes involved in DCM from gene target registry (GTR), and different miRNAs targeting these genes were identified by using bioinformatics tools NCBI, miRanda, TargetScan, miRBase, and TarBase. From the clinical data of DCM patients, we found that the number of genes are dysregulated which can be the putative target of miRNAs as they directly target these genes by binding with 8mer unit i.e STAT3 (having target binding site for miR-124-3p.1, miR125-5p), MAPK14 (targeted by miR128-3p, miR-124-3p.2, miR-124.3p.1), PRKAA1 (target site for miR-137, miR-19-3p, miR-148-3p), FOXO1 (target binding site for miR-135-3p, miR-96-5p), STK11 (putative target of miR17-5p/20-5p), and SOCS3 can be a potential target of miR-30-5p, miR-19-3p, miR-218-5p. Conclusively, we put forward the different miRNAs which are targeting the genes involved in DCM which may serve as a platform for the development of a miRNA-based therapeutic or diagnostic strategy for the treatment of diabetic cardiomyopathy.